Each transfection experiment was performed in du-
plicate at least four times. The percent conversion values shown represent the average of duplicates in a representative experiment. The variation among experiments was < 10%. The transfection efficiency (as measured by p-galactosidase activity in cell extracts) varied < 10% among all plates in a particular experiment. We have detected no toxic or growth inhibitory effects (as measured by reductions in 13-galactosidase activity or cell number) as a result of expressing WT1 or EGR-1 in transient assays. 16 18. The insertion of 3-and 17-amino acid segments into the WT1 coding sequence and the construction of chimeric wtl-egr-1 genes was accomplished with sequential PCR-mediated mutagenesis (27) . (1) . The WT1,294-429 deletion corresponded to the previously described WTZF protein (6) and included the six histidine residues at the NH2-terminus. The internally deleted protein WT1(179-294) was created by first deaving the WT1 and WTZF (6) genes at unique Bam HI sites. The restriction sites were blunted by filling in with the large fragment of DNA polymerase, and the gene fragments were fused in a blunt-end ligation reaction. The fusion of WT1 and WTZF in this manner regenerated the proper frame oftranslation and resulted in the introduction of one additional arginine residue at the site of fusion. Each gene was cloned into pGEM7Zf+ vector and used to generate synthetic RNA by in vitro transcription. The RNAs were used to program rabbit reticulocyte lysates. The DNA binding activity of each protein was assessed by gel retardation assays with a 52P-labeled oligonudeotide probe that contained an EGR binding site (6, 28 Injection of cRNA combinations that did not contain the cardiac a1 cRNA (Table 1 and Fig. 1 ), yielded small, Bay K-insensitive currents that were larger than, but otherwise similar to, the IBa of the native oocyte and were similarly (17, 18) beginning of depolarization, expressed as percent of peak amplitude (dec770) (21) . The decay of IBa became faster when the current exceeded 1.5 to 2 pLA, suggesting the interference of a current-dependent inactivation process (22) or a Ba2+-activated outward current, probably carried by C1-, since it was not observed when methanesulfonate replaced Cl-in the external solution (23) . However, in all groups, for IBa < 850 nA, the decay ofIBa did not depend on the entry of Ba2`, because (i) dec770 was independent of current amplitude, and (ii) the inactivation kinetics were not appreciably altered by replacing external Cl-with methanesulfonate (not shown). Therefore, we only analyzed inactivation kinetics of currents <850 nA.
The inactivation kinetics depended on subunit composition (Fig. 2B) . At 0 mV, the current directed by the a1 subunit alone showed little time-dependent inactivation; addition of either 1 or a2Jb to al did not significantly accelerate the decay. However, the decay was much faster in groups containing the y subunit or both aJ2/ and p ( Fig. 2B and Table 1 ). In most groups, the decay of IBa became faster with stronger the kinetics of the decay was unchanged in the range 60 to 800 nA. The "addition" of y produced the strongest acceleration (compare a1 and a1 + y, P < 0.01; a1 + a2J/ and a1 + aJ2T + y, P < 0.01; a1 + 13 and a1 + 13 + -y, P < 0.02; a1 + aJ8 + 13 and a1 + aL28 + 1 + -y, P < 0.05). depolarization, and this phenomenon did not depend on current amplitude (Fig. 3A,  C) , suggesting a voltage-dependent inactivation process (22) . The voltage dependence of the channel activation was determined mainly by al, since the current-voltage (I-V) curves of currents through channels directed by the a1 subunit alone (6, 7) are similar to those directed by most other subunit combinations (Fig. 3) . The peak of the I-V curve in most groups was between 15 and 30 mV.
However, in the al1 + aL2 + P3 group IBa activated and peaked at more negative potentials ( Fig. 3 and Table 1 ), again implying a modulation by, and a synergy between the aJb and P subunits. Addition of y to most subunit combinations slightly shifted the peak of the I-V curve to more positive voltages (Table 1 We then measured steady-state inactivation of IBa with 5-s inactivating prepulses (Fig. 4 and Table 2 ). The steady-state inactivation curves were fitted to a Boltzmann equation (24) . The inactivation of a1 subunit-directed currents showed low voltage sensitivity [half-inactivation voltage (V1/2), -7 mV)] (25). Addition of a2Jb or y, but not 1, shifted the V1/2 to negative voltages; addition of a2J and 1 jointly also reduced the slope factor Ki (that is, increased the slope of the inactivation curve). The largest effect was a strong negative shift in V112, caused in any subunit combination by the "addition" of the y subunit (Fig. 4) . The presence of -y set V112 and K1 in relatively narrow ranges (-30 to -45 mV and 13 to 20 mV, respectively). The inactivation parameters were independent of the presence of y in groups that did not contain the 27 SEPTEMBER 1991 cardiac a1, suggesting the y does not associate with the endogenous al or does not affect its properties.
In 2 mM Ba2+, V112 was shifted to more negative voltages compared to 40 mM Ba21 (Table 2) , and this change was larger in the presence of the y subunit than in its absence ( Our data and that of others (27) show that the al subunit is central in determining the kinetics and the voltage dependence of activation. This is supported by theoretical considerations (4). However, other subunits have modulatory effects: aJb (independent of the presence of 13 or y) fine tunes the activation kinetics of the cardiac channel expressed in the oocyte; as28 combined with 1 increase the voltage sensitivity of activation.
The auxiliary subunits are crucial in determining both the kinetics and voltage-dependence of the inactivation process; this result is in contrast to the fact that the inactivation properties of the voltage-dependent Na' and K' channels are determined mainly by their pore-forming subunits (28) . Addition ofaJ/, aJ2/ + 1, or y to a1 sharply increases the voltage sensitivity of the inactivation process; aJ8+P and y but not 13 also strongly accelerate the current decay. The effect of the y subunit is especially significant. Once present, y dominates the inactivation process, making it faster and more sensitive to voltage. This appears to be a voltage-rather than a Table 1 . The characteristics of IBa directed by different subunit cRNA combinations. The current amplitudes were measured at 0 mV in a solution containing 40 mM BaCI2. The entries are mean -SEM; numbers of oocytes and frogs (n, N) are indicated in the parentheses. Cd2+-subtraction procedure was used in most cases to obtain net IBa; in some cases, only leak subtraction was performed (5) . Column 2 summarizes experiments in which 3.3 to 5 ng cRNA (of each subunit) was injected into the oocyte. Column 3 relates only to cells with IBa over -10 nA in which the effect of (-) Bay K 8644 was tested. The increase in IB. caused by Bay K was calculated in each cell as [(amplitude in Bay K, % of control) -100%], where "control" denotes IBa before application of Bay K. In columns 4 to 6, the oocytes were injected with between 0.6 and 25 ng of cRNA (of each subunit) per oocyte; only cells in which net IBa was obtained by the Cd2+-subtraction procedure are summarized. In column 5, only cells in which IBa did not exceed -850 nA were taken into account.
NT, not tested. (30) . This is consistent with the presence of RNA homologous to that ofthe SM y subunit in skeletal and smooth muscle but not in the heart (12, 13 Serial human immunodeficiency virus type-1 (HIV-1) isolates were obtained from five individuals with acquired immunodeficiency syndrome (AIDS) who changed therapy to 2',3'-dideoxyinosine (ddI) after at least 12 months of treatment with 3'-azido-3'-deoxythymidine (zidovudine, AZT). The in vitro sensitivity to ddI decreased during the 12 months following ddI initiation, whereas AZT sensitivity increased. Analysis of the reverse transcriptase coding region revealed a mutation associated with reduced sensitivity to ddI. When this mutation was present in the same genome as a mutation known to confer AZT resistance, the isolates showed increased sensitivity to AZT. Analysis ofHIV-1 variants confirmed that the ddI resistance mutation alone conferred ddl and 2',3'-dideoxycytidine resistance, and suppressed the effect of the AZT resistance mutation. The use of combination therapy for HIV-1 disease may prevent drug-resistant isolates from emerging. (1) . Some individuals who have become intolerant to AZT or appear to be deteriorating clinically have changed therapy to other potentially effective drugs, including ddl (3), after discontinuing AZT. To discover if HIV isolates from such individuals develop resistance to ddI and if ddl therapy has any influence on AZT sensitivity we studied sequential isolates from five individuals who had received AZT for at least 12 months and were switched to ddI after they appeared to deteriorate clinically (4) .
HIV was recovered from peripheral blood mononuclear cells (PBMCs) by cocultivation with donor HIV-PBMCs (5), and drug sensitivity was assessed with a PBMCbased assay (6) . All isolates recovered at the time therapy was switched had reduced sensitivity to AZT. AZT therapy was discontinued and ddli started (with informed consent). Within 6 to 12 months of discontinuing AZT therapy, the isolates were substantially more sensitive to AZT. During the same time period, a 6-to 26-fold decrease in ddl sensitivity was observed. A representative sensitivity profile for isolates from one individual is illustrated in Fig. 1 . After 12 months of ddI therapy, the AZT IC50 (50% inhibitory concentration) had dropped from a high of greater than 10 liM to 0.73 pM AZT, whereas the ddl JC50's for the same isolates increased from 0.3 ILM to 9 FLM.
Studies have demonstrated that multiple common mutations in the HIV-1 reverse transcriptase (RT) coding region confer resistance to AZT (7). Variants with reduced AZT sensitivity were found to contain one or more amino acid changes at codons 67, 70, 215, or 219. To identify mutations in the RT coding region associated with the observed resistance to ddI, we determined the complete nucleotide sequence of the 10. AZT therapy was discontinued, and ddI therapy (4 mg per kilogram of body mass every 12 hours) was initiated. Blood samples were obtained as shown before, at the time of, and at various times after the change in antiviral therapy. Virus was isolated and analyzed for sensitivity to AZT and ddI as described (5, 6).
